MEP11508A - Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof - Google Patents

Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

Info

Publication number
MEP11508A
MEP11508A MEP-115/08A MEP11508A MEP11508A ME P11508 A MEP11508 A ME P11508A ME P11508 A MEP11508 A ME P11508A ME P11508 A MEP11508 A ME P11508A
Authority
ME
Montenegro
Prior art keywords
group
preparation
alkoxy
therapeutic use
halogen atom
Prior art date
Application number
MEP-115/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Francoise Bono
Michael Bosch
Santos Victor Dos
Jean Marc Herbert
Dino Nisato
Bernard Tonnerre
Jean Wagnon
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MEP11508A publication Critical patent/MEP11508A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MEP-115/08A 2002-06-07 2003-06-05 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof MEP11508A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0207001 2002-06-07
PCT/FR2003/001685 WO2003104225A1 (fr) 2002-06-07 2003-06-05 Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
MEP11508A true MEP11508A (en) 2010-06-10

Family

ID=29724874

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-115/08A MEP11508A (en) 2002-06-07 2003-06-05 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

Country Status (30)

Country Link
US (2) US7294628B2 (xx)
EP (2) EP1513835B1 (xx)
JP (2) JP4441401B2 (xx)
KR (1) KR100970812B1 (xx)
CN (1) CN100448875C (xx)
AR (2) AR040247A1 (xx)
AT (2) ATE336491T1 (xx)
AU (2) AU2003255644B2 (xx)
BR (1) BR0311828A (xx)
CA (1) CA2487840C (xx)
CY (2) CY1107330T1 (xx)
DE (2) DE60305037T2 (xx)
DK (2) DK1513835T3 (xx)
EA (1) EA007501B1 (xx)
ES (2) ES2271637T3 (xx)
HK (1) HK1076110A1 (xx)
HR (1) HRP20041157B1 (xx)
IS (1) IS2302B (xx)
MA (1) MA27233A1 (xx)
ME (1) MEP11508A (xx)
MX (1) MXPA04012341A (xx)
NO (1) NO329669B1 (xx)
NZ (1) NZ537044A (xx)
PL (1) PL208711B1 (xx)
PT (2) PT1513835E (xx)
RS (2) RS20050014A (xx)
TW (2) TWI319400B (xx)
UA (1) UA77526C2 (xx)
WO (2) WO2003104226A1 (xx)
ZA (1) ZA200409823B (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
JP2007519639A (ja) * 2004-01-08 2007-07-19 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 複素環アリル誘導体
US20070299109A1 (en) * 2004-07-16 2007-12-27 Miroslav Cik Dimeric Compounds Of Piperidine, Piperazine Or Morpholine Or Their 7-Membered Analogs Suitable For The Treatment Of Neurodegenerative Disorders
CA2580787A1 (en) * 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP1871420A4 (en) * 2005-04-15 2010-09-22 Univ North Carolina PROCESS FOR ENABLING CELL SURVIVAL VIA NEUROTROPHINE MIMETICS
JP5147866B2 (ja) * 2007-03-15 2013-02-20 メルク・シャープ・アンド・ドーム・コーポレーション グルカン合成酵素阻害剤として有用であるピリダジノン誘導体
AU2008254585B2 (en) * 2007-05-21 2013-09-26 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2932481B1 (fr) 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
IN2012DN05142A (xx) 2009-11-12 2015-10-23 Pharma Trophix Inc
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
FR2953839A1 (fr) 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
FR2953836B1 (fr) * 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
SG181570A1 (en) 2009-12-14 2012-07-30 Merck Patent Gmbh Inhibitors of sphingosine kinase
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
EP3684364A4 (en) * 2017-09-18 2021-06-02 Goldfinch Bio, Inc. PYRIDAZINONE AND METHOD OF USE THEREOF
PE20211774A1 (es) 2018-09-18 2021-09-08 Goldfinch Bio Inc Piridazinonas y sus metodos de uso
EP3858439A1 (en) * 2020-02-03 2021-08-04 Esteve Pharmaceuticals, S.A. Amide derivatives having multimodal activity against pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173180B (es) * 1987-10-26 1994-02-07 Pfizer Procedimiento para preparar agentes ansioliticos
FR2747041B1 (fr) * 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
FR2803593B1 (fr) 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
TWI319400B (en) 2010-01-11
AU2003255645A1 (en) 2003-12-22
PT1513836E (pt) 2006-09-29
DE60305037T2 (de) 2006-12-14
HRP20041157B1 (en) 2012-11-30
EP1513835A1 (fr) 2005-03-16
JP4441401B2 (ja) 2010-03-31
DE60307632T2 (de) 2007-08-09
NO329669B1 (no) 2010-11-29
DK1513836T3 (da) 2006-09-11
AU2003255644B2 (en) 2009-02-05
US20050176722A1 (en) 2005-08-11
TW200400185A (en) 2004-01-01
JP4437075B2 (ja) 2010-03-24
EA200401470A1 (ru) 2005-06-30
HRP20041157A2 (en) 2005-06-30
EP1513836A1 (fr) 2005-03-16
MA27233A1 (fr) 2005-02-01
PT1513835E (pt) 2006-12-29
EA007501B1 (ru) 2006-10-27
ZA200409823B (en) 2006-07-26
RS52588B (en) 2013-04-30
BR0311828A (pt) 2005-03-29
IS7579A (is) 2004-12-02
UA77526C2 (en) 2006-12-15
NZ537044A (en) 2006-08-31
CN100448875C (zh) 2009-01-07
EP1513835B1 (fr) 2006-08-16
JP2005533051A (ja) 2005-11-04
DK1513835T3 (da) 2006-12-27
WO2003104225A1 (fr) 2003-12-18
CA2487840C (en) 2011-05-17
KR100970812B1 (ko) 2010-07-16
DE60305037D1 (de) 2006-06-08
MXPA04012341A (es) 2005-09-30
RS20050014A (xx) 2007-06-04
CN1675203A (zh) 2005-09-28
HK1076110A1 (en) 2006-01-06
PL208711B1 (pl) 2011-05-31
EP1513836B1 (fr) 2006-05-03
US20060167007A1 (en) 2006-07-27
TW200407321A (en) 2004-05-16
NO20045331L (no) 2005-03-07
ATE325122T1 (de) 2006-06-15
KR20050008802A (ko) 2005-01-21
CA2487840A1 (en) 2003-12-18
PL374729A1 (en) 2005-10-31
AU2003255644A1 (en) 2003-12-22
CY1105784T1 (el) 2011-02-02
DE60307632D1 (de) 2006-09-28
CY1107330T1 (el) 2012-11-21
US7468368B2 (en) 2008-12-23
AR040247A1 (es) 2005-03-23
ES2264001T3 (es) 2006-12-16
IS2302B (is) 2007-10-15
ES2271637T3 (es) 2007-04-16
US7294628B2 (en) 2007-11-13
AR040246A1 (es) 2005-03-23
WO2003104226A1 (fr) 2003-12-18
TWI283671B (en) 2007-07-11
ATE336491T1 (de) 2006-09-15
JP2005534661A (ja) 2005-11-17

Similar Documents

Publication Publication Date Title
MEP11508A (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
ATE169008T1 (de) 3,5-dioxo-(2h,4h)-1,2,4-triazinderivate ihre herstellung und verwendung als medikament
HRP20040824B1 (hr) Derivati aminoindazola, postupak i međuprodukti dobiveni prilikom pripravljanja medicinskih produkata, te farmaceutski pripravci koji ih sadrže
HRP20080429T3 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
SE0302232D0 (sv) Novel Compounds
ATE503746T1 (de) Neue imidazolidinderivate
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
EA200700758A1 (ru) Новые производные бис-азаиндолов, их получение и фармацевтическое применение в качестве ингибиторов киназ
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
TW200607808A (en) Pyrido-pyrimidine derivatives, preparation thereof and application thereof
HRP20050082A2 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
DE60336735D1 (de) Neue biologischaktive molekü le
NO20082226L (no) 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav
ATE239711T1 (de) Neue allythiopyridazinderivate und verfahren zu ihrer herstellung
MX2009010243A (es) Compuestos de quinolina apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6.
MY137964A (en) Benzofuran derivative
TW200612912A (en) Benzyloxy derivatives as maob inhibitors
TNSN06337A1 (en) 6-substituted pyridoindolone derivatives production and therapeutic use thereof
AR057748A1 (es) Derivados de 2,3 dihidroindol. composiciones farmaceuticas
AR034313A1 (es) Utilizacion de derivados de piridoindolona para la preparacion de medicamentos
DE602004009306D1 (de) 3,4-dihydro-1h-chinolin-2-onderivate als norepinephrin-wiederaufnahme-hemmern
MEP25308A (en) Aminoindazole derivatives and use thereof as kinase inhibitors
HRP20060401A2 (en) Piperazine derivatives of alkyl oxindoles
MXPA04000620A (es) Uso de derivados de tiazol para elaboracion de medicamento para tratamiento de enfermedad pulmonar obstructiva cronica.
DE60214554D1 (de) Derivate von 3-phenyl-n-(2-(4-benzyl)piperidin-1-yl)ethyl) acrylamid mit ccr-3-rezeptor antagonistischer wirkung zur verwendung bei der behandlung von entzündungen und allergischen leiden